Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INDV-6001
- Development stage
- Phase 2
- Lead developer
- Indivior
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
INDV-6001 is a sustained-release long-acting injectable (LAI) prodrug of buprenorphine being developed for the treatment of opioid use disorder (OUD). It is designed to provide extended-duration treatment, which may be beneficial for patients requiring long-term medication for opioid use disorder. The drug is currently undergoing clinical evaluation to assess its pharmacokinetics, safety, and tolerability following multiple doses in participants with OUD.
- Other names
- buprenorphine depotlong-acting injectable buprenorphine
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on INDV-6001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INDV-6001.